A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 22, 2017

Primary Completion Date

July 6, 2018

Study Completion Date

July 6, 2018

Conditions
Psoriasis
Interventions
DRUG

Fumaderm

Fumaderm tablet administered orally

DRUG

risankizumab

Risankizumab administered by subcutaneous (SC) injection

Trial Locations (23)

4103

Klinik fur Dermatologie /ID# 161101, Leipzig

10117

Charité Universitätsmedizin Campus Mitte /ID# 165621, Berlin

10789

ISA GmbH /ID# 165619, Berlin

15831

Gemeinschaftspraxis /ID# 161037, Blankenfeld-mahlow

20246

Univ Klinik Eppendorf Hamburg /ID# 161038, Hamburg

20354

Tfs /Id# 160994, Hamburg

24105

Univ Hosp Schleswig-Holstein /ID# 160995, Kiel

24148

Medizinisches Versorgungszentrum DermaKiel GmbH /ID# 161102, Kiel

32429

Johannes Wesling Klin Minden /ID# 161015, Minden

42287

Centroderm Wuppertal /ID# 165615, Wuppertal

44803

Hautzentrum Niesmann Othlingha /ID# 161034, Bochum

48149

Universitatsklinikum Munster /ID# 165739, Munster

53113

Universitaetsklinikum Bonn /ID# 165618, Bonn

55131

Univ Johannes Gutenberg /ID# 161104, Mainz

56242

CMS3 Company for Medical Study /ID# 161103, Selters (Westerwald)

58453

Hoffmann, Witten, DE /ID# 165622, Witten

60590

Universitatsklinikum Frankfurt /ID# 161036, Frankfurt am Main

64297

Hautklinik Klinikum Darmstadt /ID# 164940, Darmstadt

69120

Universitaetsklinik Heidelberg /ID# 161014, Heidelberg

72076

Universitatsklinikum Tubingen /ID# 165620, Tübingen

80802

TU Uniklinik Munchen /ID# 160996, Munich

91054

Universitaetsklinikum Erlangen /ID# 161035, Erlangen

01307

Universitaetklinikum Dresden /ID# 160983, Dresden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY